Intro:
Unless you have been hiding under a rock the last 12 months you will have noticed the weight loss drug craze. GLP-1s have taken the market by storm with NVO (Novo Nordisk) and LLY (Eli Lilly) leading the way. Those two stocks are up 53% and 59% in that time on the backs of Ozempic, Wegovy and soon to be Mounjaro for Lilly. That may see like a crazy increase in valuation, but the anticipated obesity market is 100B (this doesnt even factor in heart and kidney diesease indications) and the NVO earnings reports from the last 3 Qtrs validate this narritive. 40+% increases in revenue y/y will do that for you when you’re generating billions. This brings me to ALT (Altimmune). There are a few other small bios working in this space but I want to focus here as it’s one of the lowest MC (market caps) and one of the most promising.
Leave a Reply